The estimated Net Worth of Stephen Michael Kelsey is at least $17.6 Milion dollars as of 13 August 2024. Dr Kelsey owns over 16,667 units of Revolution Medicines Inc stock worth over $11,903,928 and over the last 15 years he sold RVMD stock worth over $4,942,183. In addition, he makes $773,033 as Pres of R&D at Revolution Medicines Inc.
Sign up
Dr D RVMD stock SEC Form 4 insiders trading
Dr has made over 31 trades of the Revolution Medicines Inc stock since 2011, according to the Form 4 filled with the SEC. Most recently he exercised 16,667 units of RVMD stock worth $68,168 on 13 August 2024.
The largest trade he's ever made was exercising 39,900 units of Revolution Medicines Inc stock on 28 September 2020 worth over $188,727. On average, Dr trades about 6,583 units every 108 days since 2009. As of 13 August 2024 he still owns at least 285,740 units of Revolution Medicines Inc stock.
You can see the complete history of Dr Kelsey stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Dr. Stephen M. Kelsey FRC Path., FRCP, M.D. biography
Dr. Stephen M. Kelsey FRC Path., FRCP, M.D. is the Pres of R&D at Revolution Medicines Inc.
What is the salary of Dr D?
As the Pres of R&D of Revolution Medicines Inc, the total compensation of Dr D at Revolution Medicines Inc is $773,033. There are 4 executives at Revolution Medicines Inc getting paid more, with Mark Goldsmith having the highest compensation of $4,576,250.
How old is Dr D?
Dr D is 60, he's been the Pres of R&D of Revolution Medicines Inc since . There are 1 older and 15 younger executives at Revolution Medicines Inc. The oldest executive at Revolution Medicines Inc is Elizabeth Anderson, 62, who is the Independent Director.
What's Dr D's mailing address?
Stephen's mailing address filed with the SEC is C/O REVOLUTION MEDICINES, INC., 700 SAGINAW DRIVE, REDWOOD CITY, CA, 94063.
Insiders trading at Revolution Medicines Inc
Over the last 5 years, insiders at Revolution Medicines Inc have traded over $249,645,422 worth of Revolution Medicines Inc stock and bought 3,371,315 units worth $74,500,278 . The most active insiders traders include Peter Svennilson, Thilo Schroeder a Rock Ventures Ii, L.P.Third.... On average, Revolution Medicines Inc executives and independent directors trade stock every 11 days with the average trade being worth of $3,075,216. The most recent stock trade was executed by Stephen Michael Kelsey on 13 August 2024, trading 16,667 units of RVMD stock currently worth $68,168.
What does Revolution Medicines Inc do?
revolution medicines discovers and develops new drugs that harness the therapeutic potential of frontier oncology targets on behalf of cancer patients. our innovative product engine draws inspiration from nature and evolution, which offer insights into cancer targets, disease mechanisms and therapeutic approaches. we pay particular attention to natural products that are inherently rich with biological function as a result of natural selection and can inform and guide our discovery and development of small molecules that can modulate these targets.
What does Revolution Medicines Inc's logo look like?
Complete history of Dr Kelsey stock trades at Geron a Revolution Medicines Inc
Revolution Medicines Inc executives and stock owners
Revolution Medicines Inc executives and other stock owners filed with the SEC include:
-
Mark Goldsmith,
Chairman of the Board, President, Chief Executive Officer -
Margaret Horn,
Chief Operating Officer, General Counsel -
Steve Kelsey,
President of Research and Development -
Dr. Mark A. Goldsmith Ph.D.,
CEO, Pres & Chairman -
Dr. Stephen M. Kelsey FRC Path., FRCP, M.D.,
Pres of R&D -
Margaret A. Horn J.D.,
COO, Gen. Counsel & Sec. -
Dr. Stephen M. Kelsey M.D., FRCP, FRC Path.,
Pres of R&D -
Margaret A. Horn,
COO, Gen. Counsel & Sec. -
Xiaolin Wang,
Exec. VP of Clinical Devel. -
Dr. Mark A. Goldsmith M.D., Ph.D.,
CEO, Pres & Chairman -
Alexis Borisy,
Lead Independent Director -
Barbara Weber,
Independent Director -
Vincent Miller,
Independent Director -
Elizabeth Anderson,
Independent Director -
Peter Svennilson,
Independent Director -
Thilo Schroeder,
Independent Director -
Eric Schmidt,
Independent Director -
Neil Exter,
Independent Director -
Jack Anders,
Vice President - Finance and Principal Accounting Officer -
Dr. Martin D. Burke M.D., Ph.D.,
Co-Founder & Chairman of Scientific Advisory Board -
Jack Anders,
Sr. VP of Fin. & Principal Accounting Officer -
Luan M. Wilfong,
Sr. VP of HR -
Walter Reiher Ph.D.,
Chief Information Officer -
David L. Pompliano,
Founding Chief Scientific Officer -
Dr. Kevan M. Shokat,
Academic Co-Founder & Member of Scientific Advisory Board -
Dr. Michael A. Fischbach,
Academic Co-Founder & Member of Scientific Advisory Board -
Dr. Martin D. Burke,
Co-Founder & Chairman of Scientific Advisory Board -
Frank Clyburn,
-
Group Iii, Lpcolumn Group I...,
-
Laurence Lasky,
Director -
Group Iii, Lp Svennilson Pe...,
-
Rock Ventures Iii, L.P.Thir...,
-
Rock Ventures Iv, L.P.Third...,
-
James E Deerfield Mgmt Iv, ...,
-
Lin Wei,
Chief Medical Officer -
Jeff Cislini,
General Counsel -
Stephen Michael Kelsey,
See Remarks -
Rock Ventures Iii, L.P.Thir...,
-
Rock Ventures Iii, L.P.Thir...,
-
Xiaolin Wang,
See Remarks -
Rock Ventures Ii, L.P.Third...,
-
Rock Ventures Iii, L.P.Thir...,
-
Sushil Patel,
-
Flavia Borellini,
-
Lorence H. Kim,